Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muc1 peptide vaccine
- Development stage
- Phase 1
- Lead developer
- University of Pittsburgh
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The MUC1 peptide vaccine is a therapeutic cancer vaccine developed by Dr. Olivera Finn at the University of Pittsburgh. It consists of a synthetic peptide derived from the tandem repeat domain of the Mucin 1 (MUC1) protein, a transmembrane glycoprotein that is frequently overexpressed and abnormally hypoglycosylated in various adenocarcinomas. The vaccine is designed to induce a cellular immune response, specifically activating CD8+ and CD4+ T cells to recognize and eliminate cells expressing the tumor-associated form of MUC1 (tMUC1). In clinical settings, it is typically administered in combination with the adjuvant Hiltonol (poly-ICLC), a synthetic double-stranded RNA that acts as a Toll-like receptor 3 (TLR3) agonist to enhance the immunogenicity of the peptide. The vaccine is being investigated for immune interception and prevention in conditions such as ductal carcinoma in situ (DCIS) and colorectal adenomatous polyps.
- Other names
- MUC1 vaccineMUC-1 vaccineMUC 1 vaccineMUC1-poly-ICLC vaccineMUC-1-poly-ICLC vaccineMUC 1-poly-ICLC vaccineMUC1 peptideMUC-1 peptideMUC 1 peptide
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on muc1 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muc1 peptide vaccine.